17 November 2026
by Joanne S. Eglovitch

New FDA MAPP sheds light on clinical pharmacology reviews

FDA_HQ_260416_ALF.png
FDA headquarters in Silver Spring, Md. (credit: Ferdouns Al-Faruque)

The US Food and Drug Administration’s (FDA) Office of Translational Sciences (OTS) and the Office of Clinical Pharmacology (OCP) recently released a new manual of procedures and policies (MAPP) which outlines the good review practices (GRPs) for the clinical pharmacology review of new drug applications (NDAs) and biologics license applications (BLAs). Both offices operate under FDA’s Center for Drug Evaluation and Research (CDER).

MAPP 5100.7 serves as a new internal guideline and does not replace any existing documents.

The MAPP states that “clinical pharmacology is a multidisciplinary science. OCP reviews of NDAs and BLAs are expected to synthesize information from all relevant clinical pharmacology knowledge areas, including drug disposition, pharmacology, biomarkers, quantitative methods, drug safety, pharmacotherapy, and clinical trial methods to inform regulatory decisions.”

The MAPP outlines four key areas that should guide the clinical pharmacology review:

  • Does the available clinical pharmacology information demonstrate evidence of effectiveness?
  • Is the proposed dosage suitable for the general patient population?
  • Are alternative dosages necessary for specific subpopulations?
  • Are there clinically significant food-drug or drug-drug interactions, and what strategies are in place to manage them?

The MAPP clarifies that “an OCP Division Director or their designee serves as the final review signatory and is responsible for ensuring that the official OCP positions on review issues … are clearly stated.”

It also specifies that OCP reviewers should adhere to established user fee target dates during their reviews. Review teams are required to follow the latest OCP internal quality procedures. Additionally, regulatory project management staff should arrange formal meetings as necessary. Additionally, the MAPP encourages informal meetings and open communication among OCP review team members as well as other discipline reviewers.

“Because participation in meetings is issue-based, keeping the entire OCP review team informed of key findings is important throughout the review process. Thus, important review findings that might influence approval or labeling decisions should be discussed among the OCP review team to gain alignment prior to engaging with other members of the CDER review team. Relevant outcomes of interactions with other disciplines outside of OCP that may be relevant to the OCP review should be shared with the rest of the OCP review team,” FDA writes.

The MAPP went into effect on 10 November.

MAPP